The following tables describe appropriate handling and storage, and drug product preparation and administration procedures for antineoplastics and other selected medications often used concomitantly. The tables describe drug use under a variety of commonly encountered conditions, but do not identify all applications or conditions of product stability and compatibility. Likewise, the tables are not an exhaustive list of marketed products and should not be construed as an endorsement for any manufacturer's products or discriminating against products that were not specifically identified. Clinicians are advised to refer to product labeling for more complete information about individual products and up-to-date reference sources for information about drug compatibility and stability
The information contained in this chapter is derived from contemporary product labeling approved by the U.S. Food and Drug Administration (FDA), pharmaceutical manufacturers' websites, and, in some cases, from published studies and personal communications with pharmaceutical manufacturers
Occasionally, the package insert component of product labeling for drugs that have received FDA approval for commercial use is prefaced by prominent precautionary and warning summaries circumscribed by a rectangular border, commonly referred to as black box warnings, or, simply, boxed warnings. The boxed warnings reproduced in this chapter faithfully recapitulate the most current versions of manufacturers' product labeling available lacking only referent citations to information located elsewhere within product labeling. Referents are replaced here by an ellipsis (…). Health care providers are urged to consult the most current versions of product labeling and primary medical publications for more information
In 2001, the FDA Office of Generic Drugs requested manufacturers of sixteen similarly named drug pairs to voluntarily revise the appearance of those established drug names by enhancing distinguishing elements of otherwise very similar (look-alike) names. The Name Differentiation Project of 2001 encouraged manufacturers to supplement their applications with revised labeling that incorporated "Tall Man" letters within drug names to aid visual differentiation between those drug names with a goal toward minimizing medication errors by inappropriate drug selection, ie, capitalizing letters that aid in distinguishing between similar generic and proprietary drug names. With the exception of section titles, labeled identities, compendial names, and boxed warnings, drug names appear in this chapter with the Tall Man names and conventions established and recommended by the FDA (URL: http://www.fda.gov/Drugs/DrugSafety/MedicationErrors/ucm164587.htm [accessed February 14, 2014]) and the Institute for Safe Medication Practices, Horsham, PA. (URL: www.ismp.org [accessed, February 14, 2014])
Key to Abbreviations
Key to Abbreviations
|0.45% NaCl ||0.45% Sodium chloride injection, USP |
|0.9% NS ||0.9% Sodium chloride injection, USP |
|1/6-M SLI ||Sodium lactate injection, USP (1/6 molar [1.9%] sodium lactate) |
|3% NaCl ||3% Sodium chloride injection (hypertonic) |
|AKA ||Also known as |
|ANC ||Absolute neutrophil count |
|AUC ||Area under the concentration versus time curve |
|B0.9% NS ||Bacteriostatic (antimicrobially preserved) 0.9% sodium chloride injection |
|BSA ||Body surface area |
|BWFI ||Bacteriostatic water for injection, USP |
|CYP ||A prefix denoting cytochrome P450 enzymes |
|CSF ||Cerebrospinal fluid |
|D10W ||10% Dextrose injection, USP |
|D2.5W ||2.5% Dextrose injection, ...|
Log In to View More
If your institution is currently a subscriber
of the HemOnc Collection please sign in below.
If your institution is not a subscriber
please click here
to learn more.
Want remote access to your institution's subscription?
Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.
If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Pop-up div Successfully Displayed
This div only appears when the trigger link is hovered over.
Otherwise it is hidden from view.